Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
Crossref DOI link: https://doi.org/10.1186/s12885-016-2289-y
Published Online: 2016-04-11
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lisenko, K.
McClanahan, F.
Schöning, T.
Schwarzbich, M. A.
Cremer, M.
Dittrich, T.
Ho, A. D.
Witzens-Harig, M.
Funding for this research was provided by:
none
